08 Apr 2022 AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center Investors | Therapeutics
29 Mar 2022 Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics
03 Feb 2022 Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin Investors | Therapeutics
18 Jan 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Investors | Therapeutics
29 Nov 2021 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 Investors | Therapeutics
03 Nov 2021 Interview with Fiona McLaughlin – Avacta Chief Scientific Officer, Therapeutics Blogs | Therapeutics
29 Sep 2021 Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership Investors | Therapeutics
06 Sep 2021 Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division Investors | Therapeutics
02 Sep 2021 Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division Investors | Therapeutics